Recent Quotes (30 days)

You have no recent quotes
chg | %

Avivagen Inc  

(Public, CVE:VIV)   Watch this stock  
Find more results for CVE:CFR
1.04
-0.10 (-8.77%)
Aug 18 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.04 - 1.14
52 week 0.85 - 2.15
Open 1.14
Vol / Avg. 27,800.00/26,287.00
Mkt cap 30.33M
P/E     -
Div/yield     -
EPS -0.15
Shares 29.13M
Beta 1.18
Inst. own     -

Key stats and ratios

Q2 (Apr '17) 2016
Net profit margin -3667.11% -1707.61%
Operating margin -3667.11% -1707.61%
EBITD margin - -1611.21%
Return on average assets -116.43% -93.48%
Return on average equity -135478.00% -
CDP Score - -

Address

100 Sussex Drive
OTTAWA, ON K1A 0R6
Canada
+1-613-9498164 (Phone)
+1-613-9498164 (Fax)

Website links

Description

Avivagen Inc is a Canada-based life sciences company. It develops products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal’s own health defenses. Its segments include products based on fully-oxidized beta-carotene (OxC-beta) technology and chemistry product sales. Its OxC-beta technology is in trials as a non-antibiotic feed additive. Its products include OxC-beta Livestock, Vivamune Health Chews and Oximunol Chewable Tablets. Its Vivamune Health Chews are supplements that are suitable for pets in all life stages and can be given to dogs and cats as young as over five weeks of age. The Oximunol Chewable Tablets are available in bottles through veterinarians across the United States. The OxC-beta Livestock is available for sale in Taiwan, Thailand and the Philippines. Its customers include government agencies, global health organizations, livestock producers and end market food companies.

Officers and directors

G.F. Kym Anthony Chairman of the Board, Interim Chief Executive Officer
Chris Boland Chief Financial Officer
David Hankinson Executive Director
Drew Basek Director of Investor Relations
Graham Burton Director - Commercialization Science, Director
Louis Hui Director - Business Development
Paul Mesburis Lead Director
David G. P. Allan Director
Vanessa Grant Director
Amin I. Khalifa Independent Director